Abstract
The use of Pro-Leu-Gly-NH2 (PLG) synthezised by NAIR et al (9) and considered as MSH-release inhibiting factor (MIF-I) in the treatment of parkinsonism is based on clinical and experimental findings. It could be shown that the application of MSH leads to an aggravation of the parkinsonian symptomatology. In animal studies it was shown that PLG (MIF-I) is able to potentiate the effects of levodopa and to antagonize the effects of reserpine and oxotremorine (for review see 8, 3). The positive effects of PLG (MIF-I) on the parkinsonian symptomatology, first shown by KASTIN and BARBEAU (2) using doses of 20-40 mg , soon were confirmed by CHASE et al (4) and FISCHER et al (6) who, in addition, could demonstrate mood elevating properties of PLG (MIF-I). This latter finding was confirmed also with larger doses of PLG in parkinsonian patients (7) and patients with endo-geneous depression (5). In the present study an analysis of the levodopa potentiating effect on motor performances, mood and drive was carried out.
PLG was provided by Höchst AG Frankfurt a. M.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Barbeau A (1975) Potentiation of levodopa effect by intravenous L-propyl-L-leucyl-glycine amide in man. Lancet II: 683–684
Barbeau A, Kastin AJ (1976) Polypeptide therapy in Parkinson’s disease — a new approach. In: Birkmayer W, Hornykiewicz O (eds) Advances in Parkinsonism. Editiones Roche, Basle, p 483–487
Barbeau A, Roy M, Gonce M, Labrecque R (1979) Newer therapeutic approaches in Parkinson’s disease. In Poirier LJ, Sourkes TL, Bédard PJ (eds), Adv Neurol Vol 24, The extrapyramidal system and its disorders. Raven Press, New York, p 433–450
Chase TN, Woods AC, Lipton MA, Morris CE (1974) Hypothalamic releasing factors and Parkinson’s disease. Arch Neurol 31: 55–56
Ehrensing RH, Kastin AJ (1978) Dose-related biphasic effect of propyl-leucyl-glycinamide (MIF-I) in depression. Am J Psychiat 135: 562–566
Fischer PA, Schneider E, Jacobi P, Maxion H (1974) Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson’s syndrome. Eur Neurol 12: 360–368
Gerstenbrand F, Binder H, Grünberger J, Kozmac C, Pusch St, Reisner Th (1976) Infusion therapy with MIF (melanocyte inhibiting factor) in Parkinson’s disease. In: Birmayer W, Hornykiewicz O, (eds) Advances in Parkinsonism. Editiones Roche, Basle, p 456–461
Gonce M, Barbeau A (1978) Essais physiologiques avec le M. I. F.-I. dans la maladie de Parkinson. Rev Neurol (Paris) 134: 141–150
Nair RMG, Kastin AJ, Schally AV (1971) Isolation and structure of hypothalamic MSH release-inhibiting hormone. Biochem Biophys Res Commun 43: 1376–1381
Schneider E, Fischer P-A, Jacobi P, Reeh W (1978) Der Einfluß von MIF (Melanozyten inhibierender Faktor) auf Psychomotorik und Stimmungsverhalten von Parkinsonkranken. Arzneim Forsch (Drug Res) 28: 1296–1297
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schneider, E., Fischer, PA., Jacobi, P., Reeh, W. (1980). Agonistic Effects of MIF (MSH-Release Inhibiting Factor) in Levodopa-Treated Parkinsonian Patients. In: Mertens, H.G., Przuntek, H. (eds) Pathologische Erregbarkeit des Nervensystems und ihre Behandlung. Verhandlungen der Deutschen Gesellschaft für Neurologie, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09220-0_35
Download citation
DOI: https://doi.org/10.1007/978-3-662-09220-0_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-10214-4
Online ISBN: 978-3-662-09220-0
eBook Packages: Springer Book Archive